GeoVax Labs, Inc. (GOVX-NASDAQ)

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing multi-antigen vaccines for infectious diseases and gene-directed therapies for solid tumors. Its lead program, GEO-CM04S1, is an MVA-based COVID-19 vaccine designed to provide broader, more durable protection, particularly for immunocompromised patients who remain underserved by current mRNA vaccines. GEO-CM04S1 is in multiple Phase 2 trials as a primary vaccine in immunocompromised patients (including those with hematologic malignancies or post-transplant status) and as a booster in both patients with chronic lymphocytic leukemia (CLL) and healthy adults previously vaccinated with mRNA vaccines. In oncology, the Company’s lead asset is Gedeptin®, a gene-directed enzyme prodrug therapy that has completed a multicenter Phase 1/2 trial in advanced head and neck cancers, with a Phase 2 neoadjuvant trial (AdPNP-203) in preparation that will evaluate intra-tumoral Gedeptin with intravenous fludarabine and neoadjuvant pembrolizumab, alongside expanded preclinical work in additional solid tumors. GeoVax is also advancing GEO-MVA, a Mpox and smallpox vaccine candidate that, based on favorable European Medicines Agency advice, is expected to move directly into a single Phase 3 immunobridging trial. Supported by worldwide rights, a growing intellectual property portfolio, and scalable manufacturing plans, including a shift from egg-based to modern cell line platforms, GeoVax is led by an experienced management team focused on high-impact vaccines and immunotherapies for urgent, underserved medical needs.

* The Corporate Snapshot was last updated on November 17, 2025.